Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


APP, Second Chinese Heparin API Importer, Steps In To Fill Blood Thinner Need

This article was originally published in PharmAsia News

Executive Summary

APP Pharmaceutical, formerly Abrexis Pharmaceutical Products, is positioning itself to be a major supplier of blood thinner to hospitals and kidney-dialysis centers. The Illinois-based firm also imports some of its active ingredient from an unnamed supplier in China, but unlike the supplier of Baxter International's troubled heparin, the APP supplier in China has been inspected by the U.S. FDA. The agency acknowledged it did not inspect Baxter's supplier because it confused the name of the company. The agency moved quickly to approve APP-related facilities to avoid a national shortage of the blood-thinner. APP says it is ready to supply U.S. needs for the drug by producing its generic version of heparin at two U.S. plants. (Click here for more - a subscription may be required

You may also be interested in...

COVID-19 Could Drive UK OTC Rises

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.

Sandoz Keeps Tabs On Teva Skinny Label Ruling

As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.

Torrent Expects Indian Dapagliflozin Ruling In Q3

With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts